

Docket No.: 283125US0X PCT

rial No.: 10/541,821

Inventor: Haruo SUGIYAMA, et al.

LIST OF RELATED CASES CITED BY APPLICANT UNDER 37 CFR 1.56

Filing Date: July 11, 2005

Group: 1632

LIST OF RELATED CASES

Examiner <u>Initial</u>	Docket No.	Serial or Patent Number	Filing or <u>Issue</u> <u>Date</u>	Patent App. <u>Publication No.</u>	Inventor or Applicant
/SJH/	283125US0XPCT*	10/541,821	07/11/05		SUGIYAMA, et al.
/SJH/	283629US0PCT	10/562,486	12/27/05		SUGIYAMA
/SJH/	284034US40CONT	11/322,245	01/03/06		SUGIYAMA, et al.

Examiner

/Sheela J. Huff/

Date Considered

06/14/2007

^{*}Present Application; listed for information NFO/hah



ket No.: 283125US0X PCT

Serial No.: 10/541,821

Inventor: Haruo SUGIYAMA, et al.

LIST OF RELATED CASES CITED BY APPLICANT UNDER 37 CFR 1.56

Filing Date: July 11, 2005

Group: 1632

LIST OF RELATED CASES

Examiner <u>Initial</u>	Docket No.	Serial or Patent	Filing or Issue Date	Patent App. Publication No.	Inventor or Applicant
/SJH/	275588US96PCT	Number 10/490,873	06/17/04	US2004/0247609 A1	SUGIYAMA
	254147US40PCT	09/744,815	01/30/01		SUGIYAMA, et al.
	254149US40PCT	10/471,835	09/15/03	US2004/0097703 A1	SUGIYAMA
	275595US96PCT	10/490,865	06/17/04	US2005/0002951 A1 .	SUGIYAMA, et al.
	275596US96XPCT	10/517,600	12/13/04		SUGIYAMA, et al.
	283121US0PCT	10/527,692	03/11/05	,	SUGIYAMA
	283124US0XPCT	10/528,360	03/18/05		SUGIYAMA, et al.
	276146US40DIV	11/196,459	08/04/05	US2005/0266014 A1	SUGIYAMA, et al.
\downarrow	276141US40CONT	11/196,452	08/04/05		SUGIYAMA, et al.
/SJH/	283125US0XPCT*	10/541,821	07/11/05		SUGIYAMA, et al.
Examiner	/Sheela I Huff/	Date	Considered	06/14/2007	

Examiner

/Sheela J. Huff/

Date Considered

06/14/2007

^{*}Present Application; listed for information NFO/hah

NEET 1 OF 2

					Ē)			
Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			OF COMMERCE	ATTY DOCKET NO. 283125US0X PCT	\$	SERIAL N	10.	
(Modified)		PATENT AND TRAD	EMARK OFFICE	283125US0X PCT 4TRAD 10/541,821				
				APPLICANT				
LIST OF	REFE	RENCES CITED BY API	PLICANT	Haruo SUGIYAMA, et al.				
				FILING DATE		GROUP		
			July 11, 2005		1632	·		
				U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
/SJH/	AA	2004/0247609	12/09/04	SUGIYAMA				
	AB	2004/0097703	05/20/04	SUGIYAMA				
	AC	2005/0002951	01/06/05	SUGIYAMA et al.				
<u> </u>	AD	2005/0266014	12/01/05	SUGIYAMA et al.				
V	AE	6 034 235	03/07/00	SUGIYAMA et al.				
/SJH/	AF	6 277 832	08/21/01	SUGIYAMA et al.	[•	
			FO	REIGN PATENT DOCUMENTS				
	<u> </u>	DOCUMENT		1			TRANSLATION	
		NUMBER	DATE	COUNTRY		YES		
/SJH/	AG	02/079253	10/10/02	WO (with English abstract & equivalent 1371664)	of EP		NO	
/SJH/	АН	00/18795	04/06/00	wo			NO	
	AI	1 103 564	05/30/01	EP			NO	
/SJH/	•	OTHER RE	FERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)	·	
/SJH/	AK	1997 MARASTONI et al. "De						
		J. Med. Chem., vol. 35 2000 OKA et al. "Cancer Imr	, pages 593-5		•			
	AL	2000 OKA et al. "Cancer Imr 1873-1880 2000	, pages 593-59 munotherapy 1	98 Fargeting Wilms' Tumor Gene WT1 Produ	uct", Journ	al of Immur	nology, vol. 164, pages	
		2000 OKA et al. "Cancer Imitalia". 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000	nunotherapy 1	98 Fargeting Wilms' Tumor Gene WT1 Produ yte Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202	uct", Journ Gene WT1	al of Immur Product by	nology, vol. 164, pages y DNA Vaccination*,	
	AL	2000 OKA et al. "Cancer Imit 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999	, pages 593-59 munotherapy 1 dic T-Lymphoc junology, vol. 2 r Era for Cance	98 Fargeting Wilms' Tumor Gene WT1 Produ yte Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202 er Immunotherapy Based on the Genes to	Gene WT1	Product by	nology, vol. 164, pages DNA Vaccination", ntigens", Immunity, vol	
	AL AM	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Meland Lymphocytes", Journal	nunotherapy 1 dic T-Lymphoc unology, vol. 2 Fra for Canco ocyte Lineage- of Experimen	98 Fargeting Wilms' Tumor Gene WT1 Productive Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202 ar Immunotherapy Based on the Genes to specific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009	Gene WT1 hat Encode	Product by Cancer A a-derived T	nology, vol. 164, pages y DNA Vaccination", ntigens", Immunity, vol	
	AL AM AN	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", 1994	nunotherapy 1 dic T-Lymphocounology, vol. 2 r Era for Cancounology Era for Cancouncyte Lineage of Experimen Ining of the ger	yte Responses Elicited to Wilms' Tumor Gene WT1 Production of the Responses Elicited to Wilms' Tumor Gene WT1 Production of the Responses Elicited to Wilms' Tumor Genes to the Response of th	Gene WT1 hat Encode Melanoma	Product by Cancer A Cancer A Cognized b	nology, vol. 164, pages / DNA Vaccination", Intigens", Immunity, vol. Tumor-infiltrating by autologous T cells	
	AL AM AN	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", 1994 BRICHARD et al. "The A2 Melanomas", J. Exp 1993	nunotherapy 1 dic T-Lymphoc unology, vol. 2 Fra for Cance ocyte Lineage of Experimen ning of the ger Proc. Natl. Aca Tyrosinase G D. Med., vol. 11	graph of the state	Gene WT1 hat Encode Melanomantigen re	Product by e Cancer A a-derived T cognized b	nology, vol. 164, pages y DNA Vaccination", intigens", Immunity, vol iumor-infiltrating ny autologous T cells T Lymphocytes on HL	
	AL AM AN AO	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cylotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", I 1994 BRICHARD et al. "The A2 Melanomas", J. Exp 1993 FISK et al. "Identification specific Cytotoxic T Lyi 1995	munotherapy 1 dic T-Lymphocounology, vol. 2 de Era for Cancel cocyte Lineage of Experimen ning of the ger Proc. Natl. Aca Tyrosinase Go. Med., vol. 11 con of an Immumphocyte Line	yte Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202 er Immunotherapy Based on the Genes to especific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009 ne coding for a shared human melanoma ad. Sci., vol. 91, pages 3515-3519 ene Codes for an Antigen Recognized by 78, pages 489-495 nodominant Peptide of HER-2/neu Protoces", J. Exp. Med., vol. 181, pages 2109-25	Gene WT1 hat Encode Melanom antigen re Autologor	Product by Cancer A Cognized b Cognized b Cognized b Cognized b Cognized b	nology, vol. 164, pages y DNA Vaccination", Intigens", Immunity, vol umor-infiltrating by autologous T cells T Lymphocytes on HL	
	AL AM AN AO AP AQ	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", i 1994 BRICHARD et al. "The A2 Melanomas", J. Ext 1993 FISK et al. "Identification specific Cytotoxic T Ly 1995 TSANG et al. "Generat Patients Immunized wi pages 982-990 1995	munotherapy 1 dic T-Lymphocounology, vol. 2 r Era for Cancounce of Experimen ning of the ger Proc. Natl. Acc Tyrosinase G b. Med., vol. 12 on of an Immumphocyte Line tion of Human th Recombinate	yte Responses Elicited to Wilms' Tumor 620, no. 3, pages 195-202 er Immunotherapy Based on the Genes to specific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009 ne coding for a shared human melanoma ad. Sci., vol. 91, pages 3515-3519 ene Codes for an Antigen Recognized by 78, pages 489-495 nodominant Peptide of HER-2/neu Protoces", J. Exp. Med., vol. 181, pages 2109-2: Cytotoxic T Cells Specific for Human Carnt Vaccinia-CEA Vaccine", Journal of the	Autologore oncogene 117 cinoembry National C	Product by e Cancer A a-derived T cognized b us Cytolytic Recognized	nology, vol. 164, pages y DNA Vaccination*, Intigens*, Immunity, vol. umor-infiltrating y autologous T cells T Lymphocytes on HL by Ovarian Tumor- en Epitopes From tute, vol. 87, no. 13,	
	AL AM AN AO AP AQ AR	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cylotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", 1994 BRICHARD et al. "The A2 Melanomas", J. Exp 1993 FISK et al. "Identificatic specific Cytotoxic T Lyr 1995 TSANG et al. "General Patients Immunized wi pages 982-990 1995 CORREALE et al. "In N Specific Antigen", Jour 1997	pages 593-59 munotherapy 1 dic T-Lymphocounology, vol. 2 v Era for Cancel cocyte Lineage- of Experimen ning of the ger Proc. Natl. Aca Tyrosinase G D. Med., vol. 11 con of an Immu mphocyte Line ion of Human th Recombina	yte Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202 er Immunotherapy Based on the Genes to specific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009 me coding for a shared human melanoma ad. Sci., vol. 91, pages 3515-3519 ene Codes for an Antigen Recognized by 78, pages 489-495 modominant Peptide of HER-2/neu Protoces", J. Exp. Med., vol. 181, pages 2109-2: Cytotoxic T Cells Specific for Human Carnt Vaccinia-CEA Vaccine", Journal of the cond of Human Cytotoxic T Lymphocytes Sponal Cancer Institute, vol. 89, no. 4, pages 100-100.	Melanomantigen revaluational Concegne	Product by e Cancer A aderived T accognized by the Cancer Antige Cancer Institute Peptides De	nology, vol. 164, pages y DNA Vaccination", Intigens", Immunity, vol. Tumor-infiltrating y autologous T cells T Lymphocytes on HL by Ovarian Tumor- en Epitopes From tute, vol. 87, no. 13,	
/SJH/	AL AM AN AO AP AQ AR	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", 1994 BRICHARD et al. "The A2 Melanomas", J. Exp 1993 FISK et al. "Identification specific Cytotoxic T Lyt 1995 TSANG et al. "General Patients Immunized wipages 982-990 1995 CORREALE et al. "In N Specific Antigen", Jour 1997 MELIEF et al. "Potentia	munotherapy 1 dic T-Lymphoc unology, vol. 2 r Era for Cance ocyte Lineage of Experimen ning of the ger Proc. Natl. Aca Tyrosinase G o. Med., vol. 11 on of an Immu mphocyte Line th Recombinat ritro Generation al Immunogeni	yte Responses Elicited to Wilms' Tumor (20, no. 3, pages 195-202 er Immunotherapy Based on the Genes the Specific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009 me coding for a shared human melanoma and Sci., vol. 91, pages 3515-3519 ene Codes for an Antigen Recognized by 78, pages 489-495 modominant Peptide of HER-2/neu Protocis'', J. Exp. Med., vol. 181, pages 2109-2: Cytotoxic T Cells Specific for Human Carint Vaccinia-CEA Vaccine'', Journal of the control of Human Cytotoxic T Lymphocytes Specific for Human Cytotoxic T Lymphocytes Specific of Human Cytotoxic T Lymphocytes Specific for Hum	Melanomantigen re Autologor Autologor National Concepts 293-300	Product by Cancer A Cognized by Cytolytic Recognized Conic Antige Cancer Insti	nology, vol. 164, pages y DNA Vaccination*, Intigens*, Immunity, vol. umor-infiltrating y autologous T cells T Lymphocytes on HL by Ovarian Tumor- en Epitopes From tute, vol. 87, no. 13,	
/SJH/	AL AM AN AO AP AQ AR AS	2000 OKA et al. "Cancer Imi 1873-1880 2000 TSUBOI et al. "Cytotox Journal of Clinical Imm 2000 ROSENBERG. "A New 10, pages 281-287 1999 BAKKER et al. "Melant Lymphocytes", Journal 1994 KAWAKAMI et al. "Clo infiltrating into tumor", 1994 BRICHARD et al. "The A2 Melanomas", J. Ext 1993 FISK et al. "Identificatic specific Cytotoxic T Lyt 1995 TSANG et al. "General Patients Immunized wi pages 982-990 1995 CORREALE et al. "In N Specific Antigen", Jour 1997 MELIEF et al. "Potentia gene products", Currer 1993	munotherapy 1 dic T-Lymphoc unology, vol. 2 r Era for Cance ocyte Lineage of Experimen ning of the ger Proc. Natl. Aca Tyrosinase G o. Med., vol. 11 on of an Immu mphocyte Line th Recombinat ritro Generation al Immunogeni	Fargeting Wilms' Tumor Gene WT1 Productive Responses Elicited to Wilms' Tumor Gene WT20, no. 3, pages 195-202 For Immunotherapy Based on the Genes to especific Antigen gp100 is Recognized by tal Medicine, vol. 179, pages 1005-1009 The coding for a shared human melanoma and Sci., vol. 91, pages 3515-3519 For Ecodes for an Antigen Recognized by 78, pages 489-495 The codes for an Antigen Recognized by 78, pages 489-49	Melanomantigen re Autologor Autologor National Concepts 293-300	Product by e Cancer A a-derived T a-derived bus Cytolytic Recognized bus Cytolytic Cancer Institute Peptides Destional Referent	nology, vol. 164, pages y DNA Vaccination", Intigens", Immunity, vol. Immor-infiltrating by autologous T cells T Lymphocytes on HL I by Ovarlan Tumor- en Epitopes From tute, vol. 87, no. 13, prived from Prostate-	



EET 2 OF 2

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.				
		PATENT AND TRADEMARK OFFICE	283125US0X PCT	10/541,821				
			APPLICANT					
LIST OF	REFE	RENCES CITED BY APPLICANT	Haruo SUGIYAMA, et al.					
			FILING DATE	GROUP				
			July 11, 2005	1632				
		·	Including Author, Title, Date, Pertinent					
/SJH/	AV	725 1993	993					
/SJH/	AW	1995	Immunity to Cure Cancer*, Cell, vol. 82, p					
/SJH/	AX	Minimal Essential Epitopes*, Immuno 1995	ological Reviews, no. 146, pages 167-177					
/SJH/	AY	Locus", Cell, vol. 60, pages 509-520 1990		at the Human Chromosome 11 Wilms' Tumor				
/SJH/	AZ	GESSLER et al. "Homozygous deletion vol. 343, pages 774-778 1990	on in Wilms tumours of a zinc-finger gene	e Identified by chromosome jumping", Nature,				
	AAA							
	AAB							
	AAC							
	AAD							
	AAE							
	AAF							
	AAG							
	ААН							
	AAI							
	LAA							
	AAK							
	AAL							
Examiner		/Sheela J. Huff/		Date Considered 06/14/2007				
*Examiner: In	itial if re	eference is considered, whether or not	citation is in conformance with MPEP 60	9; Draw line through citation if not in				
contormance	and no	t considered. Include copy of this form	with next communication to applicant.					





Approved to Use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/PT	·0		Complete if Known			
000		•		Application Number	n/541821		
IN	IFORMATION	I DI	SCLOSURE	Filing Date	July 11, 2005		
S	TATEMENT I	3Y /	APPLICANT	First Named Inventor	Haruo SUGIYAMA		
				Art Unit	N/A		
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	0020-5393PUS1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°	
/SJH/ /SJH/		WO-00/18795-A WO-02/79253-A	04-09-2000			F	

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	CA**	DI MODUGNO et al., J. Immunother., 1997, Vol. 20, No. 6, pages 431 to 436					
/SJH/	CB**	MARASTONI, M et al., Eur. J. Med. Chem., 2000, Vol. 35, No. 6, pages 593 to 598					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ***CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Examiner	/Sheela J. Huff/		Date	06/14/2007
Signature	70110014 0. 114117	· · · · · · · · · · · · · · · · · · ·	Considered	06/14/2007

DRN/smt

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.